Published: 7 February 2022
Author(s): Hiroshi Ito
Issue: April 2022
Section: Letter to the Editor

According to Humphrey and colleagues, one-third of patients with intravenous insulin-dextrose (IDex) for hyperkalemia needed repeated treatments with IDex [1]. Besides, approximately 20% of patients who underwent IDex developed hypoglycemia with a serum glucose level


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.